Bristol-Myers Urges Investors To Back $74B Celgene Buy
Bristol-Myers Squibb launched a defense of its planned $74 billion takeover of Celgene on Wednesday, imploring investors to support a deal it says "represents a compelling value proposition" following a public...To view the full article, register now.
Already a subscriber? Click here to view full article